Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | UTRN | P46939 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.35 |
| ▸ | FNTA | P49354 | 2/20 | 0.34 |
| ▸ | FNTB | P49356 | 2/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005433 | 0.88 | NOTUM (0.44) | NOTUMUTRNPGGT1BFNTAFNTB | |
| SCHEMBL18005561 | 0.82 | NOTUM (0.41) | NOTUMUTRNPGGT1BKITALOX15 | |
| SCHEMBL18005405 | 0.82 | ESR1 (0.35) | ALOX15 | |
| SCHEMBL18005803 | 0.81 | NOTUM (0.45) | NOTUMUTRNPGGT1BFNTAFNTB | |
| SCHEMBL16399478 | 0.81 | KDM4E (0.45) | NOTUMALOX15 | |
| SCHEMBL18005386 | 0.80 | ALOX15 (0.45) | NOTUMUTRNALOX15 | |
| SCHEMBL18005255 | 0.80 | MAPK14 (0.36) | NOTUMPGGT1BALOX15 | |
| SCHEMBL18004810 | 0.79 | NOTUM (0.43) | NOTUMUTRNPGGT1BFNTAFNTB | |
| SCHEMBL16399661 | 0.79 | KDM4E (0.41) | NOTUMALOX15 | |
| SCHEMBL18005434 | 0.78 | NOTUM (0.42) | NOTUMUTRNPGGT1BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NOTUM 1379/4885UTRN 4246/4885PGGT1B 3728/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NOTUM 1379/4885UTRN 4246/4885PGGT1B 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.